Whitaker L, Critchley HOD. Abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol. 2016;34:54-65.
Schrager S. Abnormal uterine bleeding associated with hormonal contraception. Am Fam Physician. 2002;65(10):2073-2081.
Costescu D, Chawla R, Hughes R, et al. Discontinuation rates of intrauterine contraception due to unfavourable bleeding: a systematic review. BMC Womens Health. 2022;22(1):82-88.
Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. Contraception. 2007;76(4):267-272.
Friedlander E, Kaneshiro B. Therapeutic options for unscheduled bleeding associated with long-acting reversible contraception. Obstet Gynecol Clin North Am. 2015;42(4):593-603.
Mansour D, Korver T, Marintcheva-Petrova M, et al. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care. 2008;13(suppl 1):13-28.
Sangi-Haghpeykar H, Poindexter AN III, Bateman L, et al. Experiences of injectable contraceptive users in an urban setting. Obstet Gynecol. 1996;88(2):227-233.
Berenson AB, Odom SD, Breitkopf CR, et al. Physiologic and psychologic symptoms associated with use of injectable contraception and 20 microg oral contraceptive pills. Am J Obstet Gynecol. 2008;199(4):351.e1-351.e12.
Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Access J Contracept. 2016;7:43-52.
Warner P, Guttinger A, Glasier AF, et al. Randomized placebo-controlled trial of CDB-2914 in new users of a levonorgestrel-releasing intrauterine system shows only short-lived amelioration of unscheduled bleeding. Hum Reprod. 2010;25(2):345-353.
Darney PD, Stuart GS, Thomas MA, et al. Amenorrhea rates and predictors during 1 year of levonorgestrel 52 mg intrauterine system use. Contraception. 2018;97(3):210-214.
Alves RDMS, Rabelo MM, Andrade VR, et al. The influence of the levonorgestrel-releasing intrauterine system position on bleeding patterns in reproductive age women. Int J Gynaecol Obstet. 2019;147(3):326-331.
Madden T, Proehl S, Allsworth JE, et al. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. Am J Obstet Gynecol. 2012;206(2):129.e1-129.e8.
Oderkerk TJ, van der Heijden P, Tibosch RMG, et al. Treatment of irregular bleeding with oestradiol during long-term levonorgestrel-releasing intrauterine system (LNG-IUS) use. Front Womens Health. 2019(4):1-3.
Jensen JT, Lukkari-Lax E, Schulze A, et al. Contraceptive efficacy and safety of the 52-mg levonorgestrel intrauterine system for up to 8 years: findings from the Mirena Extension Trial. Am J Obstet Gynecol. 2022;227(6):873e1-873e12.
Gemzell-Danielsson K, Inki P, Boubli L, et al. Bleeding pattern and safety of consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS)—a multicentre prospective study. Hum Reprod. 2010;25(2):354-359.
Lal S, Kriplani A, Kulshrestha V, et al. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system. Int J Gynaecol Obstet. 2010;109(2):128-130.
Shimoni N, Choudhury T, Goldman AR, et al. Bleeding and spotting with the levonorgestrel 13.5 mg intrauterine system: the impact of insertion timing. Contraception. 2019;99(6):340-344.
Papaikonomou K, Kopp Kallner H, Söderdahl F, et al. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial [published correction appears in Hum Reprod. 2019; 34(7): 1386–1387]. Hum Reprod. 2018;33(11):2002-2009.
Sørdal T, Inki P, Draeby J, et al. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstet Gynecol. 2013;121(5):934-941.
Upawi SN, Ahmad MF, Abu MA, et al. Management of bleeding irregularities among etonogestrel implant users: Is combined oral contraceptives pills or nonsteroidal anti-inflammatory drugs the better option?. J Obstet Gynaecol Res. 2020;46(3):479-484.
Guiahi M, McBride M, Sheeder J, et al. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. Obstet Gynecol. 2015;126(3):508-513.
Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracept Reprod Health Care. 2016;21(5):361-366.
Tantiwattanakul P, Taneepanichskul S. Effect of mefenamic acid on controlling irregular uterine bleeding in DMPA users. Contraception. 2004;70(4):277-279.
Phupong V, Sophonsritsuk A, Taneepanichskul S. The effect of tranexamic acid for treatment of irregular uterine bleeding secondary to Norplant use. Contraception. 2006;73(3):253-256.
Senthong AJ, Taneepanichskul S. The effect of tranexamic acid for treatment irregular uterine bleeding secondary to DMPA use. J Med Assoc Thai. 2009;92(4):461-465.
Kaewrudee S, Taneepanichskul S, Jaisamraun U, et al. The effect of mefenamic acid on controlling irregular uterine bleeding secondary to Norplant use. Contraception. 1999;60(1):25-30.
Shoupe D. The progestin revolution: progestins are arising as the dominant players in the tight interlink between contraceptives and bleeding control. Contracept Reprod Med. 2021;6(1):3.
Slynd (drospirenone) tablets, for oral use. Highlights of prescribing information. Accessed January 6, 2024.https://slynd.com/wp-content/uploads/2019/08/prescribing-information.pdf
Kimble T, Burke AE, Barnhart KT, et al. A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen. Contracept X. 2020;2:100020.
Archer DF, Mansour D, Foidart JM. Bleeding patterns of oral contraceptives with a cyclic dosing regimen: an overview. J Clin Med. 2022;11(15):4634.
Gallo MF, Nanda K, Grimes DA, et al. 20 µg versus >20 µg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013(8):CD003989.
Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014(7):CD004695.
Hadji P, Neulen J, Schaudig K, et al. Extended-cycle versus conventional treatment with a combined oral contraceptive containing ethinylestradiol (30 µg) and levonorgestrel (150 µg) in a randomized controlled trial. Gynecol Endocrinol. 2020;36(6):513-520.
Van Vliet HAAM, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011(11):CD003553.
Weisberg E, Merki-Feld GS, McGeechan K, et al. Randomized comparison of bleeding patterns in women using a combined contraceptive vaginal ring or a low-dose combined oral contraceptive on a menstrually signaled regimen. Contraception. 2015;91(2):121-126.
Bonassi Machado R, de Melo Pompei L, Andrade R, et al. Bleeding pattern and management of unexpected bleeding/spotting with an extended regimen of a combination of ethinylestradiol 20 mcg and drospirenone 3 mg. Int J Womens Health. 2020;12:235-242.
Godfrey EM, Whiteman MK, Curtis KM. Treatment of unscheduled bleeding in women using extended- or continuous-use combined hormonal contraception: a systematic review. Contraception. 2013;87(5):567-575.
Graziottin A. The shorter, the better: a review of the evidence for a shorter contraceptive hormone-free interval. Eur J Contracept Reprod Health Care. 2016;21(2):93-105.
Lopez LM, Grimes DA, Gallo MF, et al. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013(4):CD003552.
Kaneshiro B, Edelman A, Carlson NE, et al. A randomized controlled trial of subantimicrobial-dose doxycycline to prevent unscheduled bleeding with continuous oral contraceptive pill use. Contraception. 2012;85(4):351-358.
Kaneshiro B, Edelman A, Dash C, et al. Effect of oral contraceptives and doxycycline on endometrial MMP-2 and MMP-9 activity. Contraception. 2016;93(1):65-69.
Galant C, Berlière M, Dubois D, et al. Focal expression and final activity of matrix metalloproteinases may explain irregular dysfunctional endometrial bleeding. Am J Pathol. 2004;165(1):83-94.
Salamonsen LA, Zhang J, Hampton A, et al. Regulation of matrix metalloproteinases in human endometrium. Hum Reprod. 2000;15(suppl 3):112-119.